aditya.bardia@medenrich.com

About

Dr. Aditya Bardia's work involves management Breast Cancer. Dr. Bardia has led the clinical development of antibody drug conjugate (ADC), sacituzumab govitecan, first ADC approved for patients with metastatic triple negative breast cancer. Dr.Bardia is recipient of prestigious research awards like outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO. Dr. Bardia i editorial board member of ASCO molecular oncology tumor board.